Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.29
+0.10 (+4.57%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.21
$2.37
50-Day Range
$1.99
$2.29
52-Week Range
$1.96
$3.59
Volume
48,270 shs
Average Volume
47,124 shs
Market Capitalization
$112.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

MediciNova MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
162.0% Upside
$6.00 Price Target
Short Interest
Bearish
1.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of MediciNova in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$674 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.20) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

909th out of 1,044 stocks

Pharmaceutical Preparations Industry

440th out of 510 stocks

MNOV stock logo

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings
10/26/2020
Today
11/26/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNOV
Employees
11
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+162.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,130,000.00
Pretax Margin
-2,628,577.25%

Debt

Sales & Book Value

Annual Sales
$4.04 million
Book Value
$1.49 per share

Miscellaneous

Free Float
40,855,000
Market Cap
$112.32 million
Optionable
Optionable
Beta
0.82

Social Links


Key Executives

  • Dr. Yuichi Iwaki M.D. (Age 72)
    Ph.D., Co-Founder, Pres, CEO & Exec. Director
    Comp: $777.7k
  • Dr. Kazuko Matsuda M.D. (Age 56)
    M.P.H., MPH, Ph.D., Chief Medical Officer & Director
    Comp: $564.13k
  • Mr. Jason J. Kruger CPA (Age 45)
    CFO & Principal Financial Officer
  • Dr. David H. Crean M.B.A. (Age 57)
    Ph.D., Chief Bus. Officer
  • Mr. John O'Neil CPA
    Controller













MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings
or view top-rated stocks.

What is MediciNova's stock price forecast for 2023?

1 Wall Street research analysts have issued 12-month price objectives for MediciNova's stock. Their MNOV share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 162.0% from the stock's current price.
View analysts price targets for MNOV
or view top-rated stocks among Wall Street analysts.

How have MNOV shares performed in 2022?

MediciNova's stock was trading at $2.68 at the beginning of 2022. Since then, MNOV shares have decreased by 14.6% and is now trading at $2.29.
View the best growth stocks for 2022 here
.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our MNOV earnings forecast
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.04.

What other stocks do shareholders of MediciNova own?
What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.45%), Barclays PLC (0.32%), Renaissance Technologies LLC (0.31%), Citadel Advisors LLC (0.05%) and Price T Rowe Associates Inc. MD (0.04%). Insiders that own company stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends
.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $2.29.

How much money does MediciNova make?

MediciNova (NASDAQ:MNOV) has a market capitalization of $112.32 million and generates $4.04 million in revenue each year.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 11/27/2022 by MarketBeat.com Staff